These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10762218)

  • 1. Inhibition of hyperacute transplant rejection by soluble proteins with the functional domains of CD46 and FcgammaRII.
    Lanteri MB; Powell MS; Christiansen D; Li YQ; Hogarth M; Sandrin MS; Mckenzie IF; Loveland BE
    Transplantation; 2000 Mar; 69(6):1128-36. PubMed ID: 10762218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of recombinant soluble CD46: an inhibitor of complement activation.
    Christiansen D; Milland J; Thorley BR; McKenzie IF; Mottram PL; Purcell LJ; Loveland BE
    Immunology; 1996 Mar; 87(3):348-54. PubMed ID: 8778018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro.
    Christiansen D; Milland J; Thorley BR; McKenzie IF; Loveland BE
    Eur J Immunol; 1996 Mar; 26(3):578-85. PubMed ID: 8605924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human CD46 transgenic pig model system for the study of discordant xenotransplantation.
    Diamond LE; Quinn CM; Martin MJ; Lawson J; Platt JL; Logan JS
    Transplantation; 2001 Jan; 71(1):132-42. PubMed ID: 11211178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
    Loveland BE; Milland J; Kyriakou P; Thorley BR; Christiansen D; Lanteri MB; Regensburg M; Duffield M; French AJ; Williams L; Baker L; Brandon MR; Xing PX; Kahn D; McKenzie IF
    Xenotransplantation; 2004 Mar; 11(2):171-83. PubMed ID: 14962279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.
    Kroshus TJ; Salerno CT; Yeh CG; Higgins PJ; Bolman RM; Dalmasso AP
    Transplantation; 2000 Jun; 69(11):2282-9. PubMed ID: 10868627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vivo model of hyperacute rejection: characterization and evaluation of the effect of transgenic human complement inhibitors.
    Mora M; Lazzer M; Marsicano G; Mulder LC; Carraresi L; Pieri A; Benanchi A; Grifoni D; Nuti S; Bruzzone P; Comporti M; Cortesini R; Rossini M
    Transgenic Res; 2000 Jun; 9(3):205-13. PubMed ID: 11032369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis.
    Loveland BE; Johnstone RW; Russell SM; Thorley BR; McKenzie IF
    Transpl Immunol; 1993; 1(2):101-8. PubMed ID: 8081768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and functional analysis of glycosyl-phosphatidyl inositol-linked CD46 in transgenic mice.
    Shinkel TA; Cowan PJ; Barlow H; Aminian A; Romanella M; Lublin DM; Pearse MJ; d'Apice AJ
    Transplantation; 1998 Dec; 66(11):1401-6. PubMed ID: 9869079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic expression of a CD46 (membrane cofactor protein) minigene: studies of xenotransplantation and measles virus infection.
    Thorley BR; Milland J; Christiansen D; Lanteri MB; McInnes B; Moeller I; Rivailler P; Horvat B; Rabourdin-Combe C; Gerlier D; McKenzie IF; Loveland BE
    Eur J Immunol; 1997 Mar; 27(3):726-34. PubMed ID: 9079815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities.
    Higgins PJ; Ko JL; Lobell R; Sardonini C; Alessi MK; Yeh CG
    J Immunol; 1997 Mar; 158(6):2872-81. PubMed ID: 9058824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CD46 but not CD59 in transgenic mice protects against hyperacute rejection evoked by ex vivo perfusion with human serum.
    Marquet RL; van Stijn I; van den Tol PM; Bonthuis F; Yannoutsos N; IJzermans JN
    Transplant Proc; 1997; 29(1-2):931-2. PubMed ID: 9123592
    [No Abstract]   [Full Text] [Related]  

  • 13. Kidneys derived from mice transgenic for human complement blockers are protected in an in vivo model of hyperacute rejection.
    Lazzeri M; Mora M; Mulder LC; Marsicano G; Marinucci G; Boschi M; Bruzzone P; Alfani D; Cortesini R; Rossini M
    J Urol; 1998 Apr; 159(4):1364-9. PubMed ID: 9507885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAE hybrid, on complement-mediated swine endothelial cell lysis.
    Miyagawa S; Shirakura R; Iwata K; Nakata S; Matsumiya G; Izutani H; Matsuda H; Terado A; Matsumoto M; Nagasawa S
    Transplantation; 1994 Oct; 58(7):834-40. PubMed ID: 7524206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three soluble form messages of murine CD46 are produced through alternative mRNA splicing.
    Tsujimura A; Nunoue K; Inoue N; Shida K; Kurita-Taniguchi M; Matsumoto M; Nomura M; Takeya T; Seya T
    J Biochem; 2001 Dec; 130(6):841-8. PubMed ID: 11726285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The control of hyperacute rejection by genetic engineering of the donor species.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Eye (Lond); 1995; 9 ( Pt 2)():185-9. PubMed ID: 7556715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46).
    Mead R; Hinchliffe SJ; Morgan BP
    Immunology; 1999 Sep; 98(1):137-43. PubMed ID: 10469244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possibility of prevention of hyperacute rejection by DAF and CD59 in xenotransplantation.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Seya T
    Transplant Proc; 1994 Jun; 26(3):1235-8. PubMed ID: 7518114
    [No Abstract]   [Full Text] [Related]  

  • 19. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection.
    Yannoutsos N; Ijzermans JN; Harkes C; Bonthuis F; Zhou CY; White D; Marquet RL; Grosveld F
    Genes Cells; 1996 Apr; 1(4):409-19. PubMed ID: 9135084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.
    Christiansen D; Devaux P; Réveil B; Evlashev A; Horvat B; Lamy J; Rabourdin-Combe C; Cohen JH; Gerlier D
    J Virol; 2000 May; 74(10):4672-8. PubMed ID: 10775604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.